DavidBertHallDO

PubMed

• Risankizumab, an IL-23 Inhibitor, for Ankylosing Spondylitis: Results of a Randomised, Double-Blind, Placebo-Controlled, Proof-of-Concept, Dose-Finding Phase 2 Study
  David B Hall, Paul Scholl> ;National Institutes of Health. 2018 Jun 28
• Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Co...
  Walterhouse, D. O.,Barkauskas, D. A.,Hall, D.,Ferrari, A.,De Salvo, G. L.,Koscielniak, E.,Stevens, MCG.,Martelli, H.,Seitz, G.,Rodeberg, D. A.,Shnorhavorian, M.,Dasgup...> ;J. Clin. Oncol.. 2018 Oct 24
• Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
  Feagan, B. G.,Panés, J.,Ferrante, M.,Kaser, A.,D'Haens, G. R.,Sandborn, W. J.,Louis, E.,Neurath, M. F.,Franchimont, D.,Dewit, O.,Seidler, U.,Kim, K. J.,Selinger, C.,Pa...> ;Lancet Gastroenterol Hepatol. 2018 Jul 30
• Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial.
  McIntyre, J.A., Hopley, M., Moodley, D., Eklund, M., Gray, G.E., Hall, D.B., Robinson, P., Mayers, D., Martinson, N.A.> ;PLoS Med. 2009-10-01
• Case-control exploration of relationships between early rash or liver toxicity and plasma concentrations of nevirapine and primary metabolites.
  Hall, D.B., Macgregor, T.R.> ;HIV Clin Trials. 2007-11-01
• Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.
  Baxter, J.D., Schapiro, J.M., Boucher, C.B., Kohlbrenner, V.M., Hall, D.B., Scherer, J.R., Mayers, D.L.> ;J Virol. 2006 Nov
• Seeking ethical designs for HIV clinical trials in treatment-experienced patients: an industry perspective.
  Mayers, D.L., Chung, J., Kohlbrenner, V.M., Hall, D.B., DeMasi, R.A., Neubacher, D., Buss, N.E., Salgo, M.P.> ;AIDS Res Hum Retroviruses. 2006 Nov
• A group sequential adaptive treatment assignment design for proof of concept and dose selection in headache trials.
  Hall, D. B.,Meier, U.,Diener, H. C.> ;Contemp Clin Trials. 2005 Jun
• Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
  van Leth, F., Phanuphak, P., Stroes, E., Gazzard, B., Cahn, P., Raffi, F., Wood, R., Bloch, M., Katlama, C., Kastelein, J.P., Schechter, M., Murphy, R.L., Horban, A., ...> ;PLoS Med. 2004 Oct
• Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults.
  Skowron, G., Leoung, G., Hall, D.B., Robinson, P., Lewis, R., Grosso, R., Jacobs, M., Kerr, B., MacGregor, T., Stevens, M., Fisher, A., Odgen, R., Yen-Lieberman, B.> ;J Acquir Immune Defic Syndr. 2004 Apr 1
• The control of hepatitis B virus infection with vaccine in Yupik Eskimos. Demonstration of safety, immunogenicity, and efficacy under field conditions.
  Heyward, W. L., Bender, T. R., McMahon, B. J., Hall, D. B., Francis, D. P., Lanier, A. P., Alward, W. L., Ahtone, J. L., Murphy, B. L., Maynard, J. E.> ;Am J Epidemiol. 1985 Jun
• Risk factors for Crimean-Congo hemorrhagic fever in rural northern Senegal.
  Chapman, L. E., Wilson, M. L., Hall, D. B., LeGuenno, B., Dykstra, E. A., Ba, K., Fisher-Hoch, S. P.> ;J Infect Dis. 1991 Oct
• Rift Valley fever in rural northern Senegal: human risk factors and potential vectors.
  Wilson, M. L., Chapman, L. E., Hall, D. B., Dykstra, E. A., Ba, K., Zeller, H. G., Traore-Lamizana, M., Hervy, J. P., Linthicum, K. J., Peters, C. J.> ;Am J Trop Med Hyg. 1994 Jun
• 25-hydroxyvitamin D, insulin-like growth factor-I, and bone mineral accrual during growth.
  Breen, M. E., Laing, E. M., Hall, D. B., Hausman, D. B., Taylor, R. G., Isales, C. M., Ding, K. H., Pollock, N. K., Hamrick, M. W., Baile, C. A., Lewis, R. D.> ;J Clin Endocrinol Metab. 2011 Jan
• Bone and fat relationships in postadolescent black females: a pQCT study.
  Pollock, N. K., Laing, E. M., Hamrick, M. W., Baile, C. A., Hall, D. B., Lewis, R. D.> ;Osteoporos Int. 2011 Feb
• Confidence intervals and controlled clinical trials: incompatible tools for medical research.
  Hall, D. B.> ;J Biopharm Stat. 1993 Sep
• Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.
  Murphy, R. L., Sommadossi, J. P., Lamson, M., Hall, D. B., Myers, M., Dusek, A.> ;J Infect Dis. 1999 May
• Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine.
  van Leth, F., Hall, D. B., Lange, J. M., Reiss, P.> ;HIV Med. 2006 Sep
• Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.
  Leth, F. V., Kappelhoff, B. S., Johnson, D., Losso, M. H., Boron-Kaczmarska, A., Saag, M. S., Livrozet, J. M., Hall, D. B., Leith, J., Huitema, A. D., Wit, F. W., Beij...> ;AIDS Res Hum Retroviruses. 2006 Mar
• Induction-maintenance antiretroviral therapy: proof of concept.
  Hall, D. B., Montaner, J. G., Reiss, P., Cooper, D., Vella, S., Dohnanyi, C., Myers, M., Lange, J., Conway, B.> ;AIDS. 1998 May 7
• Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1.
  Montaner, J. S., Cahn, P., Zala, C., Casssetti, L. I., Losso, M., Hall, D. B., Wruck, J., McDonough, M., Gigliotti, M., Robinson, P. A.> ;J Acquir Immune Defic Syndr. 2003 May 1
• Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and di...
  Furst, D. E., Kolba, K. S., Fleischmann, R., Silverfield, J., Greenwald, M., Roth, S., Hall, D. B., Roszko, P. J.> ;J Rheumatol. 2002 Mar
• Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term vir...
  van Leth, F., Huisamen, C. B., Badaro, R., Vandercam, B., de Wet, J., Montaner, J. S., Hall, D. B., Wit, F. W., Lange, J. M.> ;J Acquir Immune Defic Syndr. 2005 Mar 1
• Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluati...
  Crowe, B. J., Xia, H. A., Berlin, J. A., Watson, D. J., Shi, H., Lin, S. L., Kuebler, J., Schriver, R. C., Santanello, N. C., Rochester, G., Porter, J. B., Oster, M., ...> ;Clin Trials. 2009 Oct 01
• Planning and core analyses for periodic aggregate safety data reviews.
  Xia, H. A., Crowe, B. J., Schriver, R. C., Oster, M., Hall, D. B.> ;Clin Trials. 2011 Apr
• Join now to see all